Search

A literature review found that long-acting injectable cabotegravir is effective for the prevention of HIV; however, it may increase the risk of resistance to integrase strand transfer inhibitors in individuals with infection at the initiation or during the treatment process. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) pose a significant health burden,...

This study from South Carolina shows that HIV prevalence is notably higher among Black individuals, and those living in urban areas face a slightly greater risk of contracting the infection. The spread of sexually transmitted infections (STIs) has increased dramatically over the past 10 years, reaching an all-time high in 2019. STIs are not distributed...

This investigation delved into the disparities in HIV prevalence and prevention among transgender individuals in the United States. While transgender youth showed higher rates of HIV testing, they were less likely to receive HIV education and use condoms compared to their non-transgender peers. HIV in the United States disproportionately affects transgender individuals. A recent report...

HIV-1 cannot be cured even with decades of antiretroviral therapy. A new cohort study shows that the inducible, replication-competent reservoir does not decline even with prolonged antiretroviral therapy. Antiretroviral therapy (ART) has helped suppress the HIV-1 virus to almost undetectable levels among those who adhere to the treatment. There are many people living with HIV...

A new prospective study reports that omalizumab effectively manages hives in patients with chronic urticaria. Chronic urticaria impacts 0.5–1% of adults and is marked by the appearance of itchy hives with or without angioedema lasting at least 6 weeks. Physical stimuli such as pressure, cold, heat, and vibration induce hives in 20% of patients, categorized...

A new randomized clinical trial shows that pitavastatin or other statins may help reduce major cardiovascular events in those living with HIV. These benefits are not just due to LDL cholesterol reduction. HIV significantly increases atherosclerotic cardiovascular disease incidence in those living with HIV. Studies suggest that those living with HIV have twice the risk...

97.5 percent were projected to achieve virologic suppression by a median of 33 weeks Long-acting antiretroviral therapy (LA-ART) can achieve virologic suppression among people with HIV (PWH), including those with viremia, according to a study published online July 4 in the Annals of Internal Medicine. Monica Gandhi, M.D., M.P.H., from the University of California in San...

This study investigates the intricate relationship between HIV infection and mpox, a critical area where existing literature shows disparities in severity.  The goal of the study, published in The Lancet, was to examine clinical characteristics and outcomes of mpox in individuals living with HIV and low CD4 cell counts, specifically those with CD4 counts below...

Opioid agonist therapy and needle and syringe programs are effective in reducing the transmission of HIV, HCV, and injecting risk behavior, according to a recent review. The prevalence of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is associated with injecting risk behavior in people who inject drugs (PWID). This systematic review updated an...

In a cross-sectional analysis of patients with both HIV and type 2 diabetes, researchers found that African American patients had worse diabetes control than their Caucasian counterparts. This study looked at the following diabetes treatment goals: hemoglobin A1c under 7.0%, blood pressure under 140/90 mm Hg, low-density lipoprotein (LDL) cholesterol under 100 mg/dL, and smoking...